サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1378902

リンパ腫治療市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測

Lymphoma Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028
出版日: | 発行: IMARC | ページ情報: 英文 148 Pages | 納期: 2～3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.76円
リンパ腫治療市場：世界の産業動向、シェア、規模、成長、機会、2023-2028年予測
出版日: 2023年11月02日
発行: IMARC
ページ情報: 英文 148 Pages
納期: 2～3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

概要

世界のリンパ腫治療市場規模は2022年に122億米ドルに達しました。今後、IMARCグループは、2022年から2028年にかけて8.7%の成長率（CAGR）を示し、2028年までに201億米ドルに達すると予測しています。

リンパ腫は、リンパ系における異常な悪性細胞の急速な発生を特徴とするがんの一種です。通常、リンパ節、脾臓、胸腺、骨髄にある白血球（WBC）、すなわちリンパ球を標的とし、身体の免疫反応を障害します。その結果、患者はリンパ節の腫れ、高熱、体重減少、呼吸困難、疲労感を発症します。一般的に使用されるリンパ腫治療には、放射線療法、化学療法、モノクローナル抗体療法、積極的監視療法、骨髄移植、免疫療法薬などがあります。これらの治療薬は、ホジキンリンパ腫と非ホジキンリンパ腫の両方の治療に広く使用されています。

世界中で非ホジキンリンパ腫の有病率が増加していることは、市場の成長を促進する重要な要因の一つです。さらに、このような病気にかかりやすい老年人口が増加していることも、市場の成長を後押ししています。これに伴い、リンパ腫の利用可能な診断技術や治療法に関する大衆の認識が高まっていることも、市場に明るい見通しをもたらしています。病院やその他の診断センターは、がん細胞の正確な同定とタイムリーな治療のために、コンピュータ断層撮影（CT）、磁気共鳴画像法（MRI）、陽電子放射断層撮影（PET）スキャンなどの革新的な検査や画像技術を使用しています。さらに、タンパク質同士の結合を阻害し、がん細胞に対するT細胞の反応力を高める革新的な免疫チェックポイント阻害剤の開発など、さまざまな技術の進歩が市場の成長に寄与しています。その他の要因としては、腫瘍学分野における広範な研究開発（R&D）活動、ヘルスケアインフラの全体的な改善などが挙げられ、市場のさらなる牽引役となることが予想されます。

本レポートで扱う主な質問

  • 世界のリンパ腫治療市場はこれまでどのように推移し、今後数年間はどのように推移するのか？
  • COVID-19が世界のリンパ腫治療市場に与えた影響は？
  • 主要地域市場は？
  • タイプ別の市場内訳は？
  • 検査タイプ別の市場内訳は？
  • 薬剤別の市場内訳は？
  • 業界のバリューチェーンにおける様々な段階とは？
  • 業界の主要な促進要因と課題は何か？
  • 世界のリンパ腫治療市場の構造と主要プレーヤーは？
  • 業界の競合の程度は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 世界のリンパ腫治療市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：タイプ別

  • ホジキンリンパ腫
    • 市場動向
    • 市場予測
  • 非ホジキンリンパ腫
    • 市場動向
    • 市場予測

第7章 市場内訳：検査タイプ別

  • 化学療法
    • 市場動向
    • 市場予測
  • 放射線療法
    • 市場動向
    • 市場予測
  • 免疫療法
    • 市場動向
    • 市場予測
  • 標的療法
    • 市場動向
    • 市場予測
  • 生物学的療法
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 市場内訳：薬剤別

  • アドセトリス
    • 市場動向
    • 市場予測
  • リツキサン
    • 市場動向
    • 市場予測
  • オプジーボ
    • 市場動向
    • 市場予測
  • インブルビカ
    • 市場動向
    • 市場予測
  • キイトルーダ
    • 市場動向
    • 市場予測
  • レブラミド
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第9章 市場内訳：地域別

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第10章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第11章 バリューチェーン分析

第12章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第13章 価格分析

第14章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Bristol-Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd.
    • Johnson & Johnson Services, Inc.
    • Merck & Co. Inc.
    • Novartis International AG
    • Spectrum Pharmaceuticals, Inc.
    • Takeda Pharmaceutical Company Ltd.
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Lymphoma Treatment Market: Major Drivers and Challenges
  • Figure 2: Global: Lymphoma Treatment Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Lymphoma Treatment Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Lymphoma Treatment Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Lymphoma Treatment Market: Breakup by Test Type (in %), 2022
  • Figure 6: Global: Lymphoma Treatment Market: Breakup by Drug (in %), 2022
  • Figure 7: Global: Lymphoma Treatment Market: Breakup by Region (in %), 2022
  • Figure 8: Global: Lymphoma Treatment (Hodgkin Lymphoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 9: Global: Lymphoma Treatment (Hodgkin Lymphoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 10: Global: Lymphoma Treatment (Non-Hodgkin Lymphoma) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 11: Global: Lymphoma Treatment (Non-Hodgkin Lymphoma) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 12: Global: Lymphoma Treatment (Chemotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 13: Global: Lymphoma Treatment (Chemotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 14: Global: Lymphoma Treatment (Radiation Therapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 15: Global: Lymphoma Treatment (Radiation Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 16: Global: Lymphoma Treatment (Immunotherapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 17: Global: Lymphoma Treatment (Immunotherapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 18: Global: Lymphoma Treatment (Targeted Therapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 19: Global: Lymphoma Treatment (Targeted Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 20: Global: Lymphoma Treatment (Biologic Therapy) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 21: Global: Lymphoma Treatment (Biologic Therapy) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 22: Global: Lymphoma Treatment (Other Test Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 23: Global: Lymphoma Treatment (Other Test Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 24: Global: Lymphoma Treatment (Adcetris) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 25: Global: Lymphoma Treatment (Adcetris) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 26: Global: Lymphoma Treatment (Rituxan) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 27: Global: Lymphoma Treatment (Rituxan) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 28: Global: Lymphoma Treatment (Opdivo) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 29: Global: Lymphoma Treatment (Opdivo) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 30: Global: Lymphoma Treatment (Imbruvica) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 31: Global: Lymphoma Treatment (Imbruvica) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 32: Global: Lymphoma Treatment (Keytruda) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 33: Global: Lymphoma Treatment (Keytruda) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 34: Global: Lymphoma Treatment (Revlimid) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 35: Global: Lymphoma Treatment (Revlimid) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 36: Global: Lymphoma Treatment (Other Drugs) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 37: Global: Lymphoma Treatment (Other Drugs) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 38: North America: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 39: North America: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 40: United States: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 41: United States: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 42: Canada: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 43: Canada: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 44: Asia-Pacific: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 45: Asia-Pacific: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 46: China: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 47: China: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 48: Japan: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 49: Japan: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 50: India: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 51: India: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 52: South Korea: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 53: South Korea: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 54: Australia: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 55: Australia: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 56: Indonesia: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 57: Indonesia: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 58: Others: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 59: Others: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 60: Europe: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 61: Europe: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 62: Germany: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 63: Germany: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 64: France: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 65: France: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 66: United Kingdom: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 67: United Kingdom: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 68: Italy: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 69: Italy: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 70: Spain: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 71: Spain: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 72: Russia: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 73: Russia: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 74: Others: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 75: Others: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 76: Latin America: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 77: Latin America: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 78: Brazil: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 79: Brazil: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 80: Mexico: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 81: Mexico: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 82: Others: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 83: Others: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 84: Middle East and Africa: Lymphoma Treatment Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 85: Middle East and Africa: Lymphoma Treatment Market: Breakup by Country (in %), 2022
  • Figure 86: Middle East and Africa: Lymphoma Treatment Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 87: Global: Lymphoma Treatment Industry: SWOT Analysis
  • Figure 88: Global: Lymphoma Treatment Industry: Value Chain Analysis
  • Figure 89: Global: Lymphoma Treatment Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Lymphoma Treatment Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Lymphoma Treatment Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Lymphoma Treatment Market Forecast: Breakup by Test Type (in Million US$), 2023-2028
  • Table 4: Global: Lymphoma Treatment Market Forecast: Breakup by Drug (in Million US$), 2023-2028
  • Table 5: Global: Lymphoma Treatment Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 6: Global: Lymphoma Treatment Market: Competitive Structure
  • Table 7: Global: Lymphoma Treatment Market: Key Players
目次
Product Code: SR112023A3385

Abstract

The global lymphoma treatment market size reached US$ 12.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 20.1 Billion by 2028, exhibiting a growth rate (CAGR) of 8.7% during 2022-2028.

Lymphoma refers to a type of cancer characterized by the rapid development of abnormal malignant cells in the lymphatic system. It usually targets the white blood cells (WBCs), or lymphocytes, in lymph nodes, spleen, thymus and bone marrow and impairs the immune response of the body. As a result, the patient develops swelling in the lymph nodes, high fever, weight loss, dyspnea and fatigue. Some of the commonly used lymphoma therapeutics include radiation, chemo and monoclonal antibody therapy, active surveillance, bone marrow transplant and immunotherapy drugs. These therapeutics are widely used for the treatment of both Hodgkin and non-Hodgkin lymphoma.

The increasing prevalence of non-Hodgkin lymphoma across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is also driving the market growth. In line with this, the increasing awareness among the masses regarding the available diagnostic technologies and treatment alternatives for lymphoma is also creating a positive outlook for the market. Hospitals and other diagnostic centers are using innovative tests and imaging technologies, such as computed tomography (CT), Magnetic Resonance Imaging (MRI) and positron emission tomography (PET) scans, for accurate identification of the cancer cells and timely treatment. Additionally, various technological advancements, including the development of innovative immune checkpoint inhibitors, which block proteins from binding together and increase the response strength of T-cells against cancer cells, are contributing to the market growth. Other factors, including extensive research and development (R&D) activities in the field of oncology, along with overall improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global lymphoma treatment market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, test type and drug.

Breakup by Type:

Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Breakup by Test Type:

Chemotherapy

Radiation Therapy

Immunotherapy

Targeted Therapy

Biologic Therapy

Others

Breakup by Drug:

Adcetris

Rituxan

Opdivo

Imbruvica

Keytruda

Revlimid

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis International AG, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

  • How has the global lymphoma treatment market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global lymphoma treatment market?
  • What are the key regional markets?
  • What is the breakup of the market based on the type?
  • What is the breakup of the market based on the test type?
  • What is the breakup of the market based on the drug?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global lymphoma treatment market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Lymphoma Treatment Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Type

  • 6.1 Hodgkin Lymphoma
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Non-Hodgkin Lymphoma
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Test Type

  • 7.1 Chemotherapy
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Radiation Therapy
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Immunotherapy
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Targeted Therapy
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5 Biologic Therapy
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6 Others
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast

8 Market Breakup by Drug

  • 8.1 Adcetris
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Rituxan
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Opdivo
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Imbruvica
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5 Keytruda
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6 Revlimid
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast
  • 8.7 Others
    • 8.7.1 Market Trends
    • 8.7.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Abbott Laboratories
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
      • 14.3.1.3 Financials
      • 14.3.1.4 SWOT Analysis
    • 14.3.2 Bristol-Myers Squibb Company
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
      • 14.3.2.3 Financials
      • 14.3.2.4 SWOT Analysis
    • 14.3.3 Eli Lilly and Company
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
      • 14.3.3.3 Financials
      • 14.3.3.4 SWOT Analysis
    • 14.3.4 F. Hoffmann-La Roche Ltd.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
      • 14.3.4.3 SWOT Analysis
    • 14.3.5 Johnson & Johnson Services, Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
      • 14.3.5.3 Financials
      • 14.3.5.4 SWOT Analysis
    • 14.3.6 Merck & Co. Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
      • 14.3.6.3 Financials
      • 14.3.6.4 SWOT Analysis
    • 14.3.7 Novartis International AG
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
      • 14.3.7.3 Financials
      • 14.3.7.4 SWOT Analysis
    • 14.3.8 Spectrum Pharmaceuticals, Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
      • 14.3.8.3 Financials
      • 14.3.8.4 SWOT Analysis
    • 14.3.9 Takeda Pharmaceutical Company Ltd.
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
      • 14.3.9.3 Financials
      • 14.3.9.4 SWOT Analysis
    • 14.3.10 Teva Pharmaceutical Industries Ltd.
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio
      • 14.3.10.3 Financials
      • 14.3.10.4 SWOT Analysis